VLA15
Lyme Disease
Key Facts
About Valneva
Valneva is a specialty vaccine company with a mission to address unmet medical needs in infectious disease prevention. It has successfully commercialized three vaccines, including the world's first single-shot chikungunya vaccine, and is advancing a late-stage pipeline highlighted by a Lyme disease vaccine candidate developed with Pfizer. The company's strategy is built on an integrated business model, a focus on niche or neglected diseases, and strategic partnerships to maximize the value of its assets.
View full company profileAbout Valneva SE
Valneva SE is a fully integrated specialty vaccine company with a mission to address unmet medical needs in infectious diseases through prophylactic vaccines. Its strategy combines proprietary technology platforms, including the EB66® cell line, with an end-to-end business model to control development, manufacturing, and commercialization. Key achievements include the launch of the world's only licensed chikungunya vaccine, a commercial portfolio for travel health, and a robust late-stage pipeline featuring a promising Lyme disease vaccine candidate in partnership with Pfizer.
View full company profileTherapeutic Areas
Other Lyme Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Lyme Disease and Coinfections Diagnostics | Fry Laboratories | Commercial |
| Lyme Disease Diagnostic | BlueArc Biosciences | Research/Proof-of-Concept |
| Lyme Disease Vaccine | CyanVac | Preclinical |
| Next-Gen Lyme Test | Kephera Diagnostics | Development/Validation |
| Lyme Disease Diagnostic Personalization | Innatoss Laboratories | Research |